Public pharmacovigilance communication: A process calling for evidence-based, objective-driven strategies

Drug Safety

Volumn 33, Issue 12, 2010, Pages 1065-1079

  Bahri, Priya ^a  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

Author keywords

Legislation; Pharmacovigilance.

Indexed keywords

COMMUNITY; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; EVIDENCE BASED PRACTICE; HEALTH CARE PERSONNEL; HUMAN; INTERPERSONAL COMMUNICATION; MASS MEDIUM; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MEDICAL INFORMATION SYSTEM; NOTE; PATIENT CARE; PATIENT SAFETY; PHARMACIST; PRIORITY JOURNAL; PUBLIC HEALTH; RISK ASSESSMENT; RISK MANAGEMENT;

DRUG INFORMATION SERVICES; DRUG TOXICITY; EVIDENCE-BASED PRACTICE; HEALTH COMMUNICATION; HUMANS; ORGANIZATIONAL OBJECTIVES; PHARMACOEPIDEMIOLOGY; PRODUCT SURVEILLANCE, POSTMARKETING; PROFESSIONAL ROLE;

EID: 78549255598     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11539040-000000000-00000     Document Type: Note

References (90)

1. Beijer HJM, Blaey de CJ. Hospitalisations caused by adverse reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002; 24: 46-54
2. Council of Europe (CoE) Expert Group on Safe Medication Practices. Creation of a better medication safety culture in Europe: building up safe medication practices. Strasbourg: Council of Europe, 2007
3. Institute of Medicine of the National Academies. Preventing medication errors. Washington, DC: National Academies Press, 2006
4. Leendertse AJ, Egberts ACG, Stoker LJ, et al. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008; 168: 1890-6
5. Muehlberger N, Schneeweiss S, Hasford J. Adverse drug reaction monitoring cost and benefit considerations: part I. Frequency of adverse drug reactions causing hospital admissions. Pharmacoepidemiol Drug Saf 1997; 6 Suppl. 3: S71-7
6. Pouyanne P, Haramburu F, Imbs JL, et al. Admissions to hospital caused by adverse drug reactions: cross-sectional incidence study. BMJ 2000; 320: 1036
7. Boseley S. Adverse drug reactions cost NHS d2bn. The Guardian 2008 Apr 3 [online]. Available from URL: http:// www.guardian.co.uk/society/2008/apr/03/ nhs.drugsandal cohol [Accessed 2010 Aug 25]
8. National Coordinating Council for Medication Error Reporting and Prevention (NCCMERP). NCCMERP taxonomy: medication error. Rockville (MD): NCCMERP, 1989 [online]. Available from URL: http://www.nccmerp. org/aboutMedErrors.html [Accessed 2009 Jul 13]
9. Phillips J, Beam S, Brinker A, et al. Retrospective analysis of mortalities associated with medication errors. Am J Health System Pharm 2001; 58: 1835-41
10. Uppsala Monitoring Centre. Adverse reaction [definition; online]. Available from URL: http://www.who-umc.org/ DynPage.aspx?id=22673 [Accessed 2009 May 4]
11. Goettler M, Schneeweiss S, Hasford J. Adverse drug reaction monitoring-cost and benefit considerations: part II. Cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf 1997; 6 Suppl. 3: S79-90
12. Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 2006; 63: 136-47
13. World Health Organization. The importance of pharmacovigilance. Geneva: World Health Organization, 2002
14. European Commission. Volume 9A of the rules governing medicinal products in the European Union: guidelines on pharmacovigilance for medicinal products for human use. Brussels: European Commission, 2007 (revised 2008)
15. Food and Drug and Administration. Guidance for industry: development and use of risk minimization action plans. Rockville (MD): Food and Drug Administration, 2005
16. Food and Drug and Administration. Guidance for industry: good pharmacovigilance practices and pharmacoepide-miologic assessment. Rockville (MD): Food and Drug Administration, 2005
17. Food and Drug and Administration. Guidance for industry: premarketing risk assessment. Rockville (MD): Food and Drug Administration, 2005
18. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH topic E2E: pharmacovigilance planning (PvP). Geneva: ICH Secretariat, 2003
19. Czarnecki A. Intelligent risk communication: can it be improved? Drug Saf 2008; 31: 1-6
20. Edwards R, Hugman B. The challenge of effectively communicating risk-benefit information. Drug Saf 1997; 17: 216-27
21. Gigerenzer G. Reckoning with risk. London: Penguin, 2002
22. Waller PC, Evans SJW, Beard K. Drug safety and the media. Br J Clin Pharmacol 2005; 61: 123-6
23. Adams J. Risk. London: University College London Press, 1995
24. Fischhoff B, Slovic P, Lichtenstein S, et al. How safe is safe enough? A psychometric study of attitudes towards technological risks and benefits. Policy Sci 1978; 9: 127-52
25. Slovic P. Perceived risk, trust and democracy. In: Cvetkovich G, Lofstedt RE, editors. Social trust and the management of risk. London: Earthscan, 1999: 42-52
26. Uppsala Monitoring Centre. Effective communication in pharmacovigilance: the Erice report (report on the International Conference on Developing Effective Communications in Pharmacovigilane held in Erice, 24-27 September 1997, organised by the UMC, the World Health Organization, the University of Verona, the International School of Pharmacology, the Ettore Majorana Centre for Scientific Culture and supported by EQUUS Communications). Uppsala: Uppsala Monitoring Centre, 1997
27. Erice Statement 2009: communication, medicines and patient safety. Br J Clin Pharmacol 2010; 69: 207-8
28. Uppsala Monitoring Centre. Dialogue in pharmacovigilance. Uppsala: Uppsala Monitoring Centre, 2002
29. Campbell WH, Califf RM. Improving communication of drug risks to prevent patient injury: proceedings of a workshop. Pharmacoepidemiol Drug Saf 2003; 12: 183-94
30. Wrobel P, European Platform for Patients' Organisations, Science and Industry. Workshop on patients' safety: best practices on communicating risks and the value of safety to patients with chronic diseases. Brussels: EPPOSI, 2008
31. Bennett P, Calman K, editors. Risk communication and public health. Oxford: Oxford University Press, 1999
32. Ng KL, Hamby DM. Fundamentals for establishing a risk communication programme. Health Phys 1997; 73: 473-82
33. Littlejohn SW. Theories of human communication. 7th ed. Belmont (CA): Wadsworth/Thomson Learning, 2002
34. Bouder FE. A comparative analysis of risk perception related to human health issues. In: Richter IK, Berking S, Muller-Schmid R, editors. Risk society and the culture of precaution. New York: Palgrave MacMillan, 2006
35. Rimon JG. Strategic communication in public health: the way forward. Training course on "Leadership in Strategic Health Communication" provided by Johns Hopkins Bloomberg School of Public Health, Center for Communication Programs; 2007 Jun 4-22; Baltimore (MD)
36. Hornby AS, editor. Oxford advanced learner's dictionary of current English. Oxford: Oxford University Press, 1974
37. Merriam-Webster dictionary [online]. Available from URL: http://www.merriam-webster.com/dictionary [Accessed 2008 Aug 9]
38. IT Wissen, Das groXe Online-Lexikon fur Informationstechnologie [online]. Available from URL: http://www.itwissen.info/definition/lexikon/message- Nachricht-MSG. html [Accessed 2009 Apr 10]
39. International Monetary Fund Executive Board. Code of good practices on transparency in monetary and financial policies. Washington, DC: International Monetary Fund, 2000 [online]. Available from URL: http://stats.oecd.org/ glossary/detail.asp?ID=4474 [Accessed 2008 Jul 25]
40. Transparency International [online]. Available from URL: http://www.transparency.org [Accessed 2009 Apr 10].
41. Bennett P. Understanding responses to risk: some basic findings. In: Bennett P, Calman K, editors. Risk communication and public health. Oxford: Oxford University Press, 1999: 3-19
42. National Prevention Information Network. Campaigns and initiatives: health communication strategies [online]. Available from URL: http://www.cdcnpin.org/scripts/campaign/ strategy.asp [Accessed 2009 Jun 19]
43. Communication impact [newsletter]. Issue no. 24. Baltimore (MD): Health Communication Partnership at Johns Hopkins Bloomberg School of Public Health, Center for Communication Programs 2008, Jan.
44. Howson J. HIV/AIDS: an overview for strategic health communication [workshop]. Training course on "Leadership in Strategic Health Communication" provided by Johns Hopkins Bloomberg School of Public Health, Center for Communication Programs; 2007 Jun 4-22; Baltimore (MD)
45. Aston K. Communication: yes, but does it work? In: WHO Regional Office for Europe. The pen is as mighty as the surgeon's scalpel: improving health communication impact. London: The Nuffield Trust on behalf of WHO Regional Office for Europe, 1999: 29-33
46. Health Communication Partnership. The new P-process: steps in strategic communication. Baltimore (MD): Health Communication Partnership at Johns Hopkins Bloomberg School of Public Health, Center for Communication Programs, 2003
47. Renn O. Risk governance: coping with uncertainty in a complex world. London: Earthscan, 2008
48. Kotler P, Roberto N, Lee N. Social marketing: improving the quality of life. Thousand Oaks (CA): Sage, 2002
49. Williams J. Strategy development for communication development [lecture]. Training course "Leadership in Strategic Health Communication" provided by Johns Hopkins Bloomberg School of Public Health, Center for Communication Programs; 2007 Jun 4-22; Baltimore (MD)
50. Storey D. Social and behavior change communication: a social ecology approach to strategic communication [lecture]. Training course "Leadership in Strategic Health Communication" provided by Johns Hopkins Bloomberg School of Public Health, Center for Communication Programs; 200 Jun 4-22; Baltimore (MD)
51. Zenz M. Germany: status of cancer pain and palliative care. J Pain Symptom Management 1993; 8: 416-8
52. Zenz M, Zenz T, Tryba M, et al. Severe undertreatment of cancer pain: a 3-year survey of the German situation. J Pain Symptom Management 1995; 10: 187-91
53. Fainzang S. Discourse on safe drug use: symbolic logics and ethical aspects. Drug Saf 2010; 33: 623-9
54. Bongard V, Menard-Tache S, Bagheri H, et al. Perception of the risk of adverse drug reactions: differences between health professionals and non health professionals. Br J Clin Pharmacol 2002; 54: 433-6
55. Nichols V, Theriault-Dube I, Touzin J, et al. Risk perception and reasons for noncompliance in pharmacovigilance: a qualitative study conducted in Canada. Drug Saf 2009; 32: 579-90
56. Slovic P, Kraus N, Lappe H, et al. Risk perception of prescription drugs: report on a survey in Canada. Can J Public Health 1991; 82 (3): S15-20, S38-44
57. Fischhoff B, Bostrom A, Jacobs Quadrel M. Risk perception and communication. In: Detels R, McEwen J, Reaglehole R, et al., editors. Oxford textbook of public health. 4th ed. Oxford: Oxford University Press, 2002
58. Morgan MG, Fischhoff B, Bostrom A, et al. A mental models approach to HIV/AIDS. In: Morgan MG, Fischhoff B, Bostrom A, editors. Risk communication: a mental models approach. Cambridge: Cambridge University Press, 2004: 160-78
59. Frewer LJ. Public perceptions and risk communication. In: Bennett P, Calman K, editors. Risk communication and public health. Oxford: Oxford University Press, 1999: 20-32
60. Lofstedt RE. Risk management in post-trust societies. New York: Palgrave Macmillan, 2005
61. Goldman SA. Communication of medical product risk: how effective is effective enough? Drug Saf 2004; 27: 519-34
62. Ball LK, Evans G, Bostrom A. Risky business: challenges in vaccine risk communication. Pediatrics 1998; 101: 453-863
63. Bahri P. Parametrisierung von Rezeptdaten als Beitrag zur Qualitatssicherung der Arzneimittelverordnung [thesis, with summary in English: Parametrisation of prescription data as contribution to quality assurance of drug prescribing practice]. Berlin: Humboldt-Universitat zu Berlin, 1998
64. Doumit G, Gattellari M, Grimshaw J, et al. Local opinion leaders: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2007; (1): CD000125
65. Sandman PM. Responding to community outrage: strategies for effective risk communication. Fairfax (VA): American Industrial Hygiene Association, 1993
66. Goleman D. Emotional intelligence. London: Bloomsbury, 1996
67. Phelps EA. Emotion and cognition: insights from studies of the human amygdala. Ann Rev Psychol 2006; 57: 27-53 68
68. Roth G. Nachwort: Denken und Handeln. In: Sentker A, Wigger F, editors. Schaltstelle Gehirn: Denken Erkennen, Handeln [Zeit Wissen edition]. Heidelberg: Spektrum Akademischer Verlag & Zeitverlag Gerd Bucerius, 2009: 262-72
69. Burgess DC, Burgess MA, Leask J. The MMR vaccination and autism controversy in United Kingdom 1998-2005: inevitable community outrage or a failure of risk communication? Vaccine 2006; 24: 3921-8
70. Uehlecke J. Kampf gegen die Killerzellen. Zeit 2008 Jan 3; No. 2 [online]. Available from URL: http://www.zeit.de/ 2008/02/C-Serious-Games [Accessed 2010 Aug 25]
71. Cheater F, Baker R, Gillies C, et al. Tailored interventions to overcome identified barriers to change: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2005; (3): CD005470
72. Farmer AP, Legare F, Turcot L, et al. Printed educational materials: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2008; (3): CD004398
73. Forsetlund L, Bjørndal A, Rashidian A, et al. Continuing education meetings and workshops: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2001; (1): CD003030
74. O'Brien MA, Rogers S, Jamtvedt G, et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2007; (4): CD000409
75. Grimshaw JM, Shirran L, Thomas R, et al. Changing provider behavior: an overview of systematic reviews of interventions. Med Care 2001; 39 (8 Suppl. 2): II2-45
76. Thomson O'Brien MA, Oxman AD, Davis DA, et al. Educational outreach visits: effects on professional practice and healthcare outcomes [Cochrane review]. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 3. Oxford: Oxford Update Software, 2003
77. Furedi A. The public health implications of the 1995 "pill scare". Hum Reprod Update 1999; 5: 621-6
78. Renn O, Klinge A. Systemic risks: a new challenge to risk management. EMBO Reports 2004; 5: S41-6
79. Stirling A. The precautionary approach to risk appraisal. Toronto (ON): Nuclear Waste Management Organization, 2003
80. Herings RMC. Geneesmiddelen als determinant van ongevallen. Utrecht: Universiteit Utrecht, 1994
81. Brecht Ten Wolde G, Dijkstra A, Empelen Van P, et al. Psychological determinants of the intention to educate patients about benzodiazepines. Pharm World Sci 2008; 30: 336-42
82. Lagnaoui R, Depont F, Fourrier A, et al. Patterns and correlates of benzodiazepine use in the French general population. Eur J Clin Pharmacol 2004; 60: 523-9
83. McCormack B, Taylor BJ, McConville J, et al. Guidance document for the Northern Ireland Single Assessment Tool (NISAT) for the health and social care of older people. Belfast: Department of Health, Social Services and Public Safety, 2008
84. Mantel-Teeuwisse A, Straus S, Leufkens H, et al. Community pharmacists' adherence to the isotretinoin pregnancy program in the Netherlands. 7th Annual Meeting of the International Society of Pharmacovigilance; 2007 Oct 21-24; Bournemouth 85.
85. World Health Organization (WHO). World Alliance for Patient Safety: forward programme 2005. Geneva: World Health Organisation, 2005
86. Frank JR, Brien S, editors, on behalf of The Safety Competencies Steering Committee. The safety competencies: enhancing patient safety across the health professions. Ottawa (ON): Canadian Patient Safety Institute, 2008
87. Economic and Social Research Council. Towards a better map: science, the public and the media. Swindon: Economic and Social Research Council, 2003
88. Mebane FE. The importance of news media in pharmaceutical risk communication: proceedings of a workshop. Pharmacoepidemiol Drug Saf 2005; 14: 297-306
89. When science hits the headlines. Public discussion with panelists: Mellor F (Imperial College London), Mendoza N (Science Media Centre), Perry J (The Sun), Vaughan D (British Antarctic Survey)]. London: Dana Centre 2006, Nov 9 Goldacre B. Bad science. London: Fourth Estate, 2009.
90. Lowrey W, Evans W, Gower KK, et al. Effective media communication of disasters: pressing problems and recommendations. BMC Public Health 2007; 7: 97-104